Eli Lilly and Co (LLY) : Maple Capital Management reduced its stake in Eli Lilly and Co by 0.14% during the most recent quarter end. The investment management company now holds a total of 85,536 shares of Eli Lilly and Co which is valued at $6,861,698 after selling 116 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Eli Lilly and Co makes up approximately 2.41% of Maple Capital Management’s portfolio.
Other Hedge Funds, Including , Clinton Group Inc reduced its stake in LLY by selling 771 shares or 1.47% in the most recent quarter. The Hedge Fund company now holds 51,776 shares of LLY which is valued at $4,153,471. Eli Lilly and Co makes up approx 0.17% of Clinton Group Inc’s portfolio.Garcia Hamilton Associates Lpde reduced its stake in LLY by selling 589 shares or 3.56% in the most recent quarter. The Hedge Fund company now holds 15,958 shares of LLY which is valued at $1,280,151. Eli Lilly and Co makes up approx 0.74% of Garcia Hamilton Associates Lpde’s portfolio.Aull Monroe Investment Management Corp reduced its stake in LLY by selling 305 shares or 1.57% in the most recent quarter. The Hedge Fund company now holds 19,173 shares of LLY which is valued at $1,564,517. Eli Lilly and Co makes up approx 0.88% of Aull Monroe Investment Management Corp’s portfolio.Oakbrook Investments boosted its stake in LLY in the latest quarter, The investment management firm added 5,100 additional shares and now holds a total of 103,630 shares of Eli Lilly and Co which is valued at $8,455,172. Eli Lilly and Co makes up approx 0.45% of Oakbrook Investments’s portfolio.Evanson Asset Management boosted its stake in LLY in the latest quarter, The investment management firm added 50 additional shares and now holds a total of 4,954 shares of Eli Lilly and Co which is valued at $397,707. Eli Lilly and Co makes up approx 0.12% of Evanson Asset Management’s portfolio.
Eli Lilly and Co opened for trading at $78.33 and hit $78.74 on the upside on Monday, eventually ending the session at $78.6, with a gain of 0.46% or 0.36 points. The heightened volatility saw the trading volume jump to 22,03,303 shares. Company has a market cap of $86,762 M.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.